SelectImmune Pharma will implement reporting in English
SelectImmune Pharma is extending its presence on the international Pharmaceutical arena, where research & development as well as clinical study results and strategic partnerships are typically reported in English. Hence the company Board of Directors has decided to change the company reporting language to English from 2021/2022 and onwards. The web site will feature parallel documents in English and Swedish, including Annual and quarterly reports and press releases. For more information, please contact: Catharina Svanborg Chairman of the board SelectImmune Pharma AB